257 related articles for article (PubMed ID: 38673981)
1. The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum.
Vidal-Cevallos P; Sorroza-Martínez AP; Chávez-Tapia NC; Uribe M; Montalvo-Javé EE; Nuño-Lámbarri N
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673981
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis.
Saito T; Tsuchishima M; Tsutsumi M; George J
J Cell Mol Med; 2024 Jun; 28(12):e18491. PubMed ID: 38894579
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
[TBL] [Abstract][Full Text] [Related]
4. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
Vacca M; Kamzolas I; Harder LM; Oakley F; Trautwein C; Hatting M; Ross T; Bernardo B; Oldenburger A; Hjuler ST; Ksiazek I; Lindén D; Schuppan D; Rodriguez-Cuenca S; Tonini MM; Castañeda TR; Kannt A; Rodrigues CMP; Cockell S; Govaere O; Daly AK; Allison M; Honnens de Lichtenberg K; Kim YO; Lindblom A; Oldham S; Andréasson AC; Schlerman F; Marioneaux J; Sanyal A; Afonso MB; Younes R; Amano Y; Friedman SL; Wang S; Bhattacharya D; Simon E; Paradis V; Burt A; Grypari IM; Davies S; Driessen A; Yashiro H; Pors S; Worm Andersen M; Feigh M; Yunis C; Bedossa P; Stewart M; Cater HL; Wells S; Schattenberg JM; Anstee QM; ; Tiniakos D; Perfield JW; Petsalaki E; Davidsen P; Vidal-Puig A
Nat Metab; 2024 Jun; 6(6):1178-1196. PubMed ID: 38867022
[TBL] [Abstract][Full Text] [Related]
5. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
[TBL] [Abstract][Full Text] [Related]
6. Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Polyzos SA; Targher G
Curr Obes Rep; 2024 Jun; 13(2):242-255. PubMed ID: 38459229
[TBL] [Abstract][Full Text] [Related]
7. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Noureddin N; Copur-Dahi N; Loomba R
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
[TBL] [Abstract][Full Text] [Related]
8. Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Popov J; Despot T; Avelar Rodriguez D; Khan I; Mech E; Khan M; Bojadzija M; Pai N
Nutrients; 2024 May; 16(11):. PubMed ID: 38892602
[TBL] [Abstract][Full Text] [Related]
9. Extracellular Vesicles and Their Correlation with Inflammatory Factors in an Experimental Model of Steatotic Liver Disease Associated with Metabolic Dysfunction.
Keingeski MB; Longo L; Brum da Silva Nunes V; Figueiró F; Dallemole DR; Pohlmann AR; Vier Schmitz TM; da Costa Lopez PL; Álvares-da-Silva MR; Uribe-Cruz C
Metab Syndr Relat Disord; 2024 Jun; 22(5):394-401. PubMed ID: 38498801
[No Abstract] [Full Text] [Related]
10. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
[TBL] [Abstract][Full Text] [Related]
11. The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review.
Leahy C; Osborne N; Shirota L; Rote P; Lee YK; Song BJ; Yin L; Zhang Y; Garcia V; Hardwick JP
Biochem Pharmacol; 2024 May; ():116241. PubMed ID: 38697309
[TBL] [Abstract][Full Text] [Related]
12. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.
Núñez-Sánchez MÁ; Martínez-Sánchez MA; Martínez-Montoro JI; Balaguer-Román A; Murcia-García E; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez-Cáceres CM; Sledzinski T; Frutos MD; Hernández-Morante JJ; Fernández-García JC; Queipo-Ortuño MI; Ruiz-Alcaraz AJ; Mika A; Ramos-Molina B
J Clin Endocrinol Metab; 2024 Jun; 109(7):1781-1792. PubMed ID: 38217869
[TBL] [Abstract][Full Text] [Related]
13. Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis.
Chen J; Jian L; Guo Y; Tang C; Huang Z; Gao J
Antioxidants (Basel); 2024 Jun; 13(6):. PubMed ID: 38929168
[TBL] [Abstract][Full Text] [Related]
14. Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?
Sokal-Dembowska A; Jarmakiewicz-Czaja S; Ferenc K; Filip R
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791276
[TBL] [Abstract][Full Text] [Related]
15. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.
Meroni M; Longo M; Dongiovanni P
Front Endocrinol (Lausanne); 2024; 15():1411706. PubMed ID: 38846491
[TBL] [Abstract][Full Text] [Related]
16. The relevance of intestinal barrier dysfunction, antimicrobial proteins and bacterial endotoxin in metabolic dysfunction-associated steatotic liver disease.
Bergheim I; Moreno-Navarrete JM
Eur J Clin Invest; 2024 Jul; 54(7):e14224. PubMed ID: 38634717
[TBL] [Abstract][Full Text] [Related]
17. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch M; Roden M; Kahl S
Metabolism; 2024 May; ():155937. PubMed ID: 38782182
[TBL] [Abstract][Full Text] [Related]
18. Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti.
Xie W; Gan J; Zhou X; Tian H; Pan X; Liu W; Li X; Du J; Xu A; Zheng M; Wu F; Li Y; Lin Z
Cell Metab; 2024 Jun; 36(6):1269-1286.e9. PubMed ID: 38838640
[TBL] [Abstract][Full Text] [Related]
19. Hepatic glucose metabolism in the steatotic liver.
Scoditti E; Sabatini S; Carli F; Gastaldelli A
Nat Rev Gastroenterol Hepatol; 2024 May; 21(5):319-334. PubMed ID: 38308003
[TBL] [Abstract][Full Text] [Related]
20. Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?
Trinks J; Mascardi MF; Gadano A; Marciano S
World J Gastroenterol; 2024 Apr; 30(14):1982-1989. PubMed ID: 38681130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
